No black box warning on record for Tiagabine Hydrochloride

As of the latest FDA labeling reviewed, Tiagabine Hydrochloride (TIAGABINE HYDROCHLORIDE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Tiagabine Hydrochloride medicine page for the complete safety profile.

Other warnings & precautions

WARNINGS Seizures in Patients Without Epilepsy: Post-marketing reports have shown that tiagabine hydrochloride use has been associated with new onset seizures and status epilepticus in patients without epilepsy. Dose may be an important predisposing factor in the development of seizures, although seizures have been reported in patients taking daily doses of tiagabine hydrochloride as low as 4 mg/d

No black box warning on record for Tiagabine Hydrochloride

Other warnings & precautions

WARNINGS Seizures in Patients Without Epilepsy: Post-marketing reports have shown that tiagabine hydrochloride use has been associated with new onset seizures and status epilepticus in patients without epilepsy. Dose may be an important predisposing factor in the development of seizures, although seizures have been reported in patients taking daily doses of tiagabine hydrochloride as low as 4 mg/d

Tiagabine Hydrochloride Black Box Warning

No black box warning on record for Tiagabine Hydrochloride

Other warnings & precautions

Tiagabine Hydrochloride Black Box Warning

No black box warning on record for Tiagabine Hydrochloride

Other warnings & precautions